Table 2 Hazard ratio for HIV acquisition by HPV status

From: HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition

HPV Status

Person years (N)

# HIV events

HIV IR/100py (95% CI)

Hazard Ratioa (95% CI)

p-value

Baseline

Baseline HPV Negative (reference)

331.4 (204)

8

2.4 (1.0–4.8)

Prevalent HPV

882.1 (575)

58

6.6 (5.0–8.5)

2.5 (1.2–5.3)

0.015

# prevalent types < 3

513.1 (328)

22

4.3 (2.7–6.5)

1.7 (0.8–3.9)

0.201

# prevalent types ≥  3

369.0 (247)

36

9.8 (6.8–13.5)

3.8 (1.7–8.2)

<0.001

Prevalent Oncogenic types

625.5 (404)

46

7.4 (5.4–9.8)

2.8 (1.3–6.0)

0.008

Prevalent Non-oncogenic types

256.6 (171)

12

4.7 (2.4–8.2)

1.9 (0.8–4.7)

0.179

Prevalent Cervarix® types

203.2 (131)

12

5.9 (3.1–10.3)

2.0 (0.8–5.1)

0.151

Prevalent Gardasil® types

261.7 (171)

18

6.9 (4.1–10.9)

2.6 (1.1–6.2)

0.035

Prevalent Gardasil®9 types

495.9 (322)

36

7.3 (5.1–10.0)

2.7 (1.2–6.0)

0.012

Non-Gardasil®9 types

386.2 (253)

22

5.7 (3.6–8.6)

2.2 (0.9–5.1)

0.054

Longitudinal

Category 1: Remained HPV negative (reference)

178.6 (108)

2

1.1 (0.1–4.0)

Overlapping HPV Categories

Acquired any HPV types

633.1 (405)

49

7.7 (5.7–10.2)

9.2 (2.1–40.5)

0.003

Cleared any HPV types

747.3 (477)

54

7.2 (5.4–9.4)

6.3 (1.5–26.3)

0.012

Persisted any HPV types

358.7 (236)

28

7.8 (5.2–11.3)

6.4 (1.5–27.4)

0.013

Mutually Exclusive HPV Categories

Category 2: Only Cleared

218.5 (130)

8

3.7 (1.6–7.2)

2.2 (0.4–11.0)

0.333

Category 3: Only Acquired

141.6 (85)

6

4.2 (1.6–9.2)

5.5 (0.9–33.6)

0.068

Category 4: Only Persisted

52.5 (33)

1

1.9 (0–10.6)

0.8 (0.0–21.4)

0.888

Category 5: Cleared and Persisted

90 (61)

6

6.7 (2.4–14.5)

6.4 (1.3–32.2)

0.024

Category 6: Cleared and Acquired

275.3 (178)

22

8.0 (5.0–12.1)

7.8 (1.8–34.3)

0.006

Category 7: Persisted and Acquired

52.8 (34)

3

5.7 (1.2–16.6)

5.6 (0.9–34.5)

0.061

Category 8: Cleared, Acquired, and Persisted

163.4 (108)

18

11 (6.5–17.4)

10.2 (2.3–45.6)

0.002

  1. aAdjusted for the following baseline covariates: treatment group, age, age of sexual debut, number of sexual partners, number of sex acts (past 30 days), presence of STI, HSV-2 status, condom use, marital status, and whether women were living with regular partners. CI, confidence interval